Tech Company Financing Transactions
Shattuck Labs Funding Round
Shattuck Labs, based in Durham, secured $118 million from Redmile Group, Avidity Partners and EcoR1 Capital Management.
Transaction Overview
Company Name
Announced On
6/16/2020
Transaction Type
Venture Equity
Amount
$118,000,000
Round
Series B
Investors
Proceeds Purpose
The proceeds from the financing will be used to support the continued clinical development of SL-172154 (SIRPα-Fc-CD40L), a wholly-owned fusion protein that combines CD47 inhibition with CD40 co-stimulation, and SL-279252 (PD1-Fc-OX40L), Shattuck's lead PD1 asset being developed in collaboration with Takeda Pharmaceuticals.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
21 Parmer Way 200
Durham, NC 27709
USA
Durham, NC 27709
USA
Phone
Website
Email Address
Overview
Shattuck (Nasdaq: STTK) is developing a breakthrough platform for immunotherapy, which harnesses the human immune system to improve outcomes for patients battling cancer and inflammatory disease. Shattuck's proprietary technology represents the next evolutionary step in cancer therapy by endowing one molecule with multiple, synergistic functions.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 6/16/2020: 4Degrees venture capital transaction
Next: 6/16/2020: Augmedics venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC transactions reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs